You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

92 Results
Guidelines and Advice
Status: Archived
ID: 9-8
Mar 2014
Guidelines and Advice
Status: Archived
ID: 11-8
Version: 2
Oct 2015
Guidelines and Advice
Status: Current
ID: GL 2-21
Version: 2
Mar 2024
Guidelines and Advice
Status: Current
ID: 2-19
Jan 2017
Guidelines and Advice
Status: Current
ID: 4-3
Version: 4
Jul 2017
Guidelines and Advice
Status: Current
ID: ES 11-13
Feb 2021
Guidelines and Advice
Status: In-Review
ID: GL END 3-24
Aug 2022
Guidelines and Advice
Status: Archived
ID: 20-3
Jan 2016
Guidelines and Advice
Status: Current
ID: 8-7
Version: 2
Mar 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
selpercatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025

Pages